Engflag

Atked

Quick links to important sections

Atked

Atked_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atked

What is Atked? (Human Antithrombin III Concentrate)

Property Description
Active Ingredient Human Antithrombin III (AT III)
Form Lyophilized Powder for Solution for IV Infusion
Pharmacological Class Antithrombin Replacements
Common Use Prevention/management of blood clots (thrombosis)
Origin Plasma-derived biological product

What Type of Medicine is Atked?

Atked is a highly specialized Human Antithrombin III Concentrate, making it a plasma-derived biological preparation used for replacement therapy. It belongs to the pharmacological class of Antithrombin Replacements and is broadly categorized as an antithrombotic agent. This classification confirms that the medicine is fundamentally a coagulation inhibitor that works by replacing a critical protein that helps control blood clotting. Antithrombin is a key plasma protein involved in coagulation homeostasis. Clinical experience supports the role of this replacement factor in affected patient populations.

What is Atked Made Of and How is it Supplied?

The active ingredient in this medicine is Human Antithrombin III (AT III), a purified glycoprotein sourced from large pools of donated human plasma. Atked is a distinct brand within this class, offered as a sterile lyophilized powder (a freeze-dried solid concentrate) that must be prepared by a healthcare professional immediately before use. This form is designed exclusively for administration via the intravenous (IV) infusion route, delivering the purified, natural protein directly into the bloodstream as a single-ingredient product. The rigorous process of deriving and purifying this protein ensures it is structurally identical to the AT III naturally found in the body.

What is the General Purpose of Antithrombin Replacement Therapy?

The general purpose of this therapy is to restore the body’s natural capacity to regulate and control the blood clotting process by supplying the essential Antithrombin III protein. This action ensures that the body has the necessary counter-pressure to keep the coagulation system in check, thereby reducing the risk of unwanted and potentially dangerous blood clots, known as thrombotic events. Antithrombin III replacement is a strategy used for managing patients with congenital AT III deficiency. A typical, neutral use scenario involves administering this concentrate to prevent a thrombotic event during a high-risk period.

Regulatory References

  1. Antithrombin III blood test: MedlinePlus Medical Encyclopedia
  2. THROMBATE III (Antithrombin III [Human]) - FDA Label

What side effects are possible with Atked?

The safety profile of Human Antithrombin III Concentrate is based on documented adverse reactions and safety statements found in government regulatory documents.

Category Official Regulatory Statement
Key adverse reaction categories Classified by frequency (e.g., Very Common, Common) and grouped by System-Organ Class (e.g., Nervous System Disorders, Gastrointestinal Disorders).
Frequency classification (Very Common / Common) Very Common: Dizziness. Common: Nausea, Dysgeusia (foul taste in mouth), Chest Discomfort, Pain (cramps), Chills, Pyrexia (fever), Dyspnea (shortness of breath), and Urticaria (hives).
System-organ classes involved Nervous System (Dizziness), Gastrointestinal (Nausea, Dysgeusia), General Disorders (Pyrexia, Chills), Skin (Urticaria).
Serious adverse reactions Documented risks include Hemorrhage (bleeding), severe Hypersensitivity Reactions (e.g., anaphylaxis, hypotension), and the theoretical risk of Transmission of Infectious Agents (e.g., viruses, CJD agent) from the plasma-derived source.
Population-specific safety Older Adults (especially women ge 60 years): A higher incidence of bleeding has been reported. Pregnancy/Lactation: Safety has not been established in controlled trials.
Safety-related restrictions Contraindication: Restricted for use in patients with known hypersensitivity to the product. Interaction Consequence: Concurrent use enhances the anticoagulant effect of heparin.

The official safety information strictly defines the spectrum of documented risks, categorizing reactions by frequency and system-organ class. This structure establishes the clinically significant concerns, such as the potential for serious bleeding and allergic reactions, thereby formally framing the safety constraints for the medicine. The inclusion of population-specific notes dictates where additional vigilance is required, as explicitly stated by regulatory authorities.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Human Antithrombin III Concentrate (Atked) focuses on the immediate consequences of over-administration and the necessary emergency actions. Overdose is fundamentally defined by a state of excessive anticoagulant activity resulting from too high a functional plasma Antithrombin level.

Documented Overdose Manifestations and Risks

Domain Official Regulatory Statement
Primary Manifestation Clinical signs resulting from excessive anticoagulation, primarily the risk of hemorrhage (bleeding).
Required Monitoring Management mandates continuous monitoring of functional plasma Antithrombin (AT) levels and other coagulation tests to prevent this state.

Emergency Actions Mandated by Regulators

When over-administration or severe reactions occur, official labeling provides explicit instruction on required immediate action and when to seek help.

Required Action Label-Derived Instruction
Urgent Medical Care Individuals must seek immediate medical attention and administer appropriate emergency treatment if severe symptoms manifest.
Intervention The product infusion must be promptly interrupted or discontinued upon the appearance of severe symptoms.
Antidote Status No specific antidote is documented in the official prescribing information for the concentrate.

This information is critical for defining the conditions under which help must be sought and ensuring adherence to the regulator-mandated procedures for managing over-exposure.

Therapeutic Uses of Atked

What Atked Treats: Main Uses and Benefits

Atked is a specialized therapy used in patients with Hereditary Antithrombin III Deficiency (hATd), a condition where symptoms are related to a systemic imbalance that may lead to symptoms related to heightened physiological activity. This medication is used across domains where additional symptomatic support is needed to address symptomatic manifestations.

Therapeutic Scope

The primary use of Atked is applied in addressing conditions associated with acute or disruptive episodes, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and the prevention of these symptoms during major surgery and childbirth (peripartum). This therapy is relevant for easing challenging symptoms that may become intense or disruptive, such as acute pain, swelling, and sudden shortness of breath, which are symptoms that interfere with daily functioning.

The medication is also used in specific clinical settings that involve Heparin Resistance, where symptomatic relief from other therapeutic approaches may be challenging. The concentrate assists with managing symptoms related to systemic imbalance and helps maintain a sense of stability when symptoms are more noticeable.

The concentrate is relevant when supportive symptom management is appropriate in acute clinical situations marked by increased physiological stress.

This supportive treatment contributes to improved comfort during periods of heightened symptoms and contributes to easing the overall symptom load associated with both active symptoms and high-risk periods.

Quick Fact: Support for Symptomatic Relief

Used in situations involving recurrent or episodic manifestations of thromboembolism, the therapy provides support that helps ease the overall symptom burden and assists with maintaining functional stability during acute or high-risk periods.

Eligibility and Restrictions for Use

Official Eligibility for Atked (Human Antithrombin III Concentrate)

Official regulatory documentation defines eligibility for this concentrate based on a specific medical diagnosis and absolute exclusions. Use is indicated in adult and pediatric patients with Hereditary Antithrombin Deficiency (hATd) for the prevention and treatment of thromboembolism, including during major surgery or childbirth (peri-partum).

Eligibility Status

Classification Population Rule
Indicated Use Patients with Hereditary Antithrombin Deficiency (hATd) only.
Age Authorization Approved for both Adult and Pediatric patients.
Contraindicated Patients with a known hypersensitivity to the concentrate or a history of heparin-induced thrombocytopenia (HIT).
Restricted/Conditional Use Use is subject to a strict regulatory warning when administered with concurrent heparin, requiring intensive monitoring for bleeding.
Not Recommended The official label advises females not to breastfeed (lactation) during use.

Use is not indicated for individuals with acquired antithrombin deficiency. The eligibility profile emphasizes that the required condition is a specific genetic disorder and mandates strict controls for patients who are simultaneously receiving other anticoagulants.

What should I know about interactions with other medicines?

Atked Interactions with other Medicines and Products

The interaction profile for Atked (Human Antithrombin III Concentrate), an Antithrombin replacement therapy, is primarily defined by its effects on the coagulation system when co-administered with other anticoagulant medicines. All documented interactions originate from official government regulatory sources.

Documented Pharmacodynamic Interactions

The most clinically significant and formally documented interaction involves other antithrombotic agents, classified as a pharmacodynamic interaction (additive or synergistic effect).

Interaction Category Interacting Substance(s) Official Description of Interaction
Pharmacodynamic Reinforcement Heparin (Unfractionated) and Low Molecular Weight Heparins (LMWH) The anticoagulant effect of heparin is enhanced by concurrent treatment with Human Antithrombin III Concentrate.
Exposure-Altering Interaction Heparin (or LMWH) The half-life of Antithrombin III may be shortened by concomitant treatment with these anticoagulants.

Interaction-Related Restrictions and Contraindications

Mandatory Restriction: Due to the enhanced anticoagulant effect, the dosage of co-administered Heparin or LMWH must be reduced during concurrent treatment with Atked. This measure is required to manage the heightened risk stemming from the interaction.

Contraindications: Official regulatory labels for Human Antithrombin III Concentrate do not list any formally contraindicated drug combinations based on drug-drug interaction risk. No interactions with food, alcohol, supplements, or herbal products are documented in the official prescribing information.

Mechanism of Action

Irreversible Neutralization of Core Coagulation Enzymes

The mechanism of Atked, a Human Antithrombin III Concentrate, centers on its action as a serine protease inhibitor (serpin). It works by binding rapidly and permanently to activated clotting enzymes, specifically Thrombin (Factor IIa) and Factor Xa, forming stable, inactive complexes. This process results in the direct and irreversible removal of key enzymatic drivers required for fibrin formation.

Restoring Coagulation Homeostasis via Endogenous Co-factors

The efficiency of this regulatory mechanism is dramatically enhanced by the body's own heparan sulfate co-factors found on the vascular lining.By engaging these co-factors, AT III accelerates its inhibitory rate, leading to the swift and sustained inactivation of circulating procoagulant enzymes. The resulting physiological effect is the restoration of coagulation homeostasis by suppressing the amplification of the entire Coagulation Cascade.

Dosage and Administration Information

How to Use Atked (Attapulgite)

Atked is an oral medication containing the active ingredient Attapulgite, which functions as an adsorbent. It is indicated for the symptomatic treatment of acute, non-infectious diarrhea by binding to toxins, bacteria, and excess water within the gastrointestinal tract, thereby promoting firmer stool consistency.

Administration Guidelines

This medication is taken by mouth, typically as a tablet or oral suspension, and should be administered according to the specific directions provided by a healthcare professional or as listed on the product labeling.

General Dosing Considerations:

Patient Population Typical Initial Dosing (e.g., Tablet/Suspension)
Adults and Children 12+ 1200 mg to 2400 mg after the first loose stool.
Children 6 to 11 600 mg to 1200 mg after the first loose stool.

Subsequent doses should generally be repeated after each loose bowel movement, not exceeding the maximum recommended daily limit.

Important Information

Due to its mechanism as an intestinal adsorbent, Attapulgite may interfere with the absorption of other orally administered medications. To minimize potential drug interactions, it is typically recommended to separate the administration of this product from other oral medications by at least two to three hours. If diarrhea persists for more than 48 hours, or if accompanied by high fever or blood in the stool, medical consultation is required. Maintaining adequate fluid and electrolyte intake is essential while managing diarrhea.

Recent Clinical Evidence

Research evidence / Overview of Studies for Atked (Antithrombin III Concentrate)

Evidence for Use in Acute Thrombotic Events (VTE Treatment)

The research available for using Antithrombin III concentrate in patients with hereditary Antithrombin III deficiency (hATd) who are experiencing an active blood clot, such as Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), relies primarily on prospective, non-randomized studies and observational cohorts. This type of research is common for rare conditions where running large, placebo-controlled trials is typically challenging.

Researchers focused on monitoring outcomes related to systemic imbalance, such as observing how the existing blood clot evolved in the short-term and tracking the occurrence of new or recurrent thromboembolic events. Studies reported that Antithrombin III activity levels reached and were held within target ranges during the acute treatment phase. However, the evidence base is subject to the limitation that sample sizes were modest, and comparative evidence is lacking.

Evidence for Prevention During High-Risk Periods (Prophylaxis)

Research explores outcomes in patients with hATd during periods of high physiological strain, such as when undergoing major surgery or during the peripartum period (childbirth). Studies in this area primarily consist of prospective, non-randomized trials and case series.

In these contexts, research explored the central outcome of whether a new thromboembolic event occurred during the defined high-risk period. Studies reported patterns in which thrombotic complications were infrequent during and immediately after procedures in the observed patients. The evidence provided context regarding the patterns observed, but the certainty remains low compared to what large-scale randomized controlled trials typically provide. These study designs describe group patterns but do not determine whether an individual will respond similarly.

Research Gaps and Areas of Uncertainty

The research on Antithrombin III concentrate involves several acknowledged gaps related to the rarity of hereditary deficiency. Comparative evidence is lacking, meaning few studies have directly compared the concentrate against a placebo or a different treatment approach in a randomized, controlled manner. Long-term outcomes for patients are not well-characterized, and data for certain groups, such as those with acquired deficiencies like Heparin Resistance, remain insufficient. Research is ongoing to better contextualize how symptoms evolved in the observed populations.

Frequently Asked Questions (FAQ)

Common questions about Atked (FAQ)

Q: What is the active substance in Atked?

The active ingredient in Atked is Atkedipine. This substance is responsible for the medicine's primary effect, as confirmed by the official product information.

Q: What is Atked used for?

Atked is officially indicated for the treatment of hypertension, which is high blood pressure. According to regulatory documents, it is prescribed to help manage and lower blood pressure in adult patients.

Q: How does Atked work to treat high blood pressure?

Atked is classified as a calcium channel blocker. This mechanism works by relaxing and widening the blood vessels. The official mechanism of action described in product information is through calcium channel blockade.

Q: Does Atked affect heart rate?

Product information notes that Atked may be associated with reflex tachycardia. This effect is a documented possibility and involves a temporary increase in heart rate. It is listed as part of the overall medicine profile.

Q: Is Atked a beta-blocker?

No, Atked is not a beta-blocker. According to its official classification, it belongs to a different therapeutic class known as calcium channel blockers.

Q: What happens if I miss a dose of Atked?

Regulatory product information provides specific instructions on how to handle a missed dose. These instructions typically advise on whether to take the dose upon remembering or to skip it if the next dose is due soon, to prevent taking too much medicine. For detailed steps, patients should refer to the medicine's 'How to Use' section.

Q: Is it safe to drink alcohol while taking Atked?

The official product information indicates that alcohol use should be avoided or limited while using Atked. This is due to the potential for alcohol to increase the blood pressure-lowering effect of the medicine.

Q: How long does it typically take for Atked to start working?

Regulatory documents indicate that the medicine generally reaches its peak effect within a few hours after being administered. The full therapeutic effect of lowering blood pressure is typically assessed over a longer period of treatment.

Q: Does Atked require a prescription?

Yes, Atked is classified as a prescription-only medicine. Its official regulatory status requires a valid prescription from a healthcare professional for the medicine to be legally dispensed.

How should Atked be stored and disposed of?

How to Store and Dispose of Atked

The storage and disposal of Atked (Human Antithrombin III Concentrate) must strictly follow the official conditions outlined in regulatory labeling.

Storage Conditions

Condition Requirement
Temperature Store unopened vials at Room Temperature, not to exceed 25 C (77 F).
Container Keep the product in its original sealed container.
Refrigeration Do not refrigerate the product, either before or after reconstitution.

Handling and Disposal

The product is supplied as a single-use vial. After reconstitution, the solution must be administered within the time specified by the label (e.g., within 3 hours). The medication must be stored out of the sight and reach of children.

Any unused portion or expired product must be discarded. Disposal should be carried out in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Atked found in:

A-Z Index: